The short version of analytical characterisation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
=== Pharmacodynamics === Research has shown that salvinorin A is a potent κ-opioid receptor (KOR) agonist (Ki = 2.4 nM, EC50 = 1.8 nM). It has a high affinity for the receptor, indicated by the low dissociation constant of 1.0 nanomolar (nM). It shows atypical properties as an agonist of the KOR relative to other KOR agonists. In addition to its KOR agonism, salvinorin A has been found to act as a dopamine D2 receptor partial agonist, with an affinity of 5–10 nM, an intrinsic activity of 40–60%, and an EC50 of 48 nM. As such, the dopamine D2 receptor might also play a role in its effects. Salvinorin A has no action at the 5-HT2A serotonin receptor, the principal molecular target responsible for the actions of 'classical' psychedelics such as LSD and mescaline. Salvinorin A has also been shown to have effect on cannabinoid CB1 receptors. It significantly increases prolactin and inconsistently increases cortisol. It causes dysphoria by stopping release of dopamine in the striatum. Salvinorin A increases activity of DAT while decreasing activity of SERT. Salvinorin A is capable of inhibiting excess intestinal motility (e.g. diarrhea), through its potent κ-opioid-activating effects. The mechanism of action for salvinorin A on ileal tissue has been described as 'prejunctional', as it was able to modify electrically induced contractions, but not those of exogenous acetylcholine.
== Risks == Administration of ACAM2000 poses risks and may cause side effects. Most people who have taken the vaccine only report mild reactions. Reactions may include a sore arm, fever, and body aches. Some people may have more serious side effects, including effects that may be life-threatening. According to the FDA-approved prescribing information leaflet, "Common adverse events include inoculation site signs and symptoms, lymphadenitis, and constitutional symptoms, such as malaise, fatigue, fever, myalgia, and headache." These reactions are less frequent in people being revaccinated than those receiving the vaccine for the first time. No known contraindications exist to receiving the vaccine in case of an outbreak emergency. Furthermore, it is recommended that the vaccine should be given to pregnant women who have been exposed to smallpox. "Because the risk of maternal serious illness or death, prematurity, miscarriage, or stillbirth from a smallpox infection are greater than the risk of the vaccination, smallpox vaccine is recommended and should be offered to pregnant women in case of an outbreak emergency."
Estrogen sulfates like estradiol sulfate or estrone sulfate are about twice as potent as the corresponding free estrogens in terms of estrogenic effect when given orally to rodents. This in part led to the introduction of conjugated estrogens (Premarin), which are primarily estrone sulfate, in 1941. Although inactive at steroid hormone receptors, E2S has been found to act as a potent inhibitor of glutathione S-transferase, an enzyme that contributes to the inactivation of estradiol via conversion of it into an estradiol-glutathione conjugate. As such, E2S can indirectly serve as a positive effector of estrogen signaling. Estradiol levels are about 1.5- to 4-fold higher than E2S levels in women. This is in contrast to E1S, the levels of which are about 10 to 15 times higher than those of estrone. E2S at an oral dosage of 5 mg/day in women resulted in inhibition of ovulation in 89% of cycles (47 of 53).
The Azanian People's Liberation Army admitted to killing ten policemen in 1986 in Sharpeville alone, and in the first half of 1987 the police recorded that their members in the Vaal Triangle had been the victims of thirty-eight incidents of arson, thirty-one incidents of "intimidation", and thirty-nine incidents of stoning. In some cases, attacks on policemen were retributive, with policemen accused of having carried out assassinations of or other attacks on local political activists; residents of Sharpeville also claimed that the police themselves engaged in retributive attacks, creating a "cycle of violence". Research suggests that school principals – particularly unpopular ones and those seen to be aiding the police – were an additional target for attacks from about January 1986 onwards.
=== Participation === Individuals with dwarfism are capable of actively participating in various aspects of society. They have access to education and sports, and can pursue careers, engaging in a wide range of professions.
Sources: en.wikipedia.org
=== NT-501 === NT-501 is a product being developed by Neurotech that consists of encapsulated human cells genetically modified to secrete ciliary neurotrophic factor (CNTF). In a clinical trial, NT-501 demonstrated a statistically significant reduction of photoreceptor degradation in patients with retinitis pigmentosa.
Based on modeled and observed accumulated cyclone energy (ACE), El Niño years usually result in less active hurricane seasons in the Atlantic Ocean, but instead favor a shift to tropical cyclone activity in the Pacific Ocean, compared to La Niña years favoring above average hurricane development in the Atlantic and less so in the Pacific basin. Over the Atlantic Ocean, vertical wind shear is increased, which inhibits tropical cyclone genesis and intensification, by causing the westerly winds to be stronger. The atmosphere over the Atlantic Ocean can also be drier and more stable during El Niño events, which can inhibit tropical cyclone genesis and intensification. Within the Eastern Pacific basin: El Niño events contribute to decreased easterly vertical wind shear and favor above-normal hurricane activity. However, the impacts of the ENSO state in this region can vary and are strongly influenced by background climate patterns. The Western Pacific basin experiences a change in the location of where tropical cyclones form during El Niño events, with tropical cyclone formation shifting eastward, without a major change in how many develop each year. As a result of this change, Micronesia is more likely, and China less likely, to be affected by tropical cyclones. A change in the location of where tropical cyclones form also occurs within the Southern Pacific Ocean between 135°E and 120°W, with tropical cyclones more likely to occur within the Southern Pacific basin than the Australian region.
There are many reasons why an excited state can be metastable. The most common mechanism is by suppression of gamma decay of excited nuclei, making the decay route a forbidden transition. Spin is conserved, and a photon has spin 1 ħ. Thus, if a decay route would require a change of ≥ 2 ħ (any possible change is always integer) in angular momentum, then the gamma decay would become highly suppressed. For example, if the decay requires the nucleus to change spin by 2 ħ, then it must emit 2 photons at once. This is a 3-body interaction, which is much weaker than a 2-body interaction, and thus occurs at a much lower rate. In general, each additional unit of spin larger than 1 that the emitted gamma ray must carry inhibits decay rate by about 5 orders of magnitude. As the excited energy state lowers, eventually internal conversion (IC) and internal pair production (IP) takes over. The decay of 180mTa from spin-9 state to spin-2 state changes spin by 7 ħ. This suppresses the rate of gamma emission so much that the decay rate is essentially equal to the rate of IC, in agreement with the above. When the nucleus begins and ends with 0 spin, it cannot decay via single photo gamma emission. The only possible routes are IC, internal pair production, or two-photon gamma emission. Usually IC and IP dominates over two-photon gamma emission.
=== Weight change === Metformin use is typically associated with weight loss. It appears to be safe and effective in counteracting the weight gain caused by the antipsychotic medications olanzapine and clozapine. Although modest reversal of clozapine-associated weight gain is found with metformin, primary prevention of weight gain is more valuable.
Sources: en.wikipedia.org
== Education and credentialing == Clinical pharmacists have extensive education in the biomedical, pharmaceutical, socio-behavioural and clinical sciences. Most clinical pharmacists have a Doctor of Pharmacy (Pharm.D.) degree and many have completed one or more years of post-graduate training (for example, a general and/or specialty pharmacy residency). In the United States, clinical pharmacists can choose to become Board-certified through the Board of Pharmacy Specialties (BPS), which was organized in 1976 as an independent certification agency of the American Pharmacists Association. The BPS certifies pharmacists in the following specialties:
=== Names === Esketamine is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while esketamine hydrochloride is its BANMTooltip British Approved Name, Modified. It is also known as S(+)-ketamine, (S)-ketamine, or (–)-ketamine ((-)[+] ketamine), as well as by its developmental code name JNJ-54135419. Esketamine is sold under the brand name Spravato for use as an antidepressant and the brand names Eskesia, Ketanest, Ketanest S, Ketanest-S, Keta-S for use as an anesthetic (veterinary), among others.
This concept is of clinical interest as it is sometimes necessary to reach a certain concentration of a drug that is known to be optimal in order for it to have the required effects on the organism (as occurs if a patient is to be scanned).
The hypothesis was put forward in 2012 and Benton, et al. named the cycle in 2017 after its inventor, the Swiss biochemist, nutritionist and exercise physiologist Dr. Serge Summermatter. The concept of the Summermatter cycle finds broad application in body weight management to time exercise interventions and avoid catch-up fat (yo-yo effect). The recent advances in the treatment of obesity (e.g., GLP-1 and GIP agonists like Ozempic, Wegovy etc.) has further spurred interest in the Summermatter cycle. Treatments with incretins like semaglutide induce not only fat but also muscle mass loss. The suppressed thermogenesis described by the Summermatter cycle explains the weight and fat regain in patients that discontinue incretins. Moreover, the concept is used by elite athletes to optimally coordinate their training bouts and energy intake.
== Further reading == Snyder, Lloyd R.; Kirkland, Joseph J.; Dolan, John W. (2009). Introduction to Modern Liquid Chromatography. doi:10.1002/9780470508183. ISBN 978-0-470-16754-0. Dong, Michael W. (2006). Modern HPLC for Practicing Scientists. doi:10.1002/0471973106. ISBN 978-0-471-72789-7. Snyder, Lloyd R.; Kirkland, Joseph J.; Glajch, Joseph L. (1997). Practical HPLC Method Development. doi:10.1002/9781118592014. ISBN 978-0-471-00703-6. Ahuja, Satinder; Rasmussen, Henrik (2007). HPLC Method Development for Pharmaceuticals. Elsevier Science. ISBN 978-0-12-370540-2. Ahuja, Satinder; Dong, M. W. (2005). Handbook of pharmaceutical analysis by HPLC (1st ed.). Amsterdam Boston: Elsevier Academic Press. ISBN 978-0-12-088547-3. Kazakevich, Yuri; Lobrutto, Rosario, eds. (2007). HPLC for Pharmaceutical Scientists. doi:10.1002/0470087951. ISBN 978-0-471-68162-5. Neue, Uwe D. (1997). HPLC columns: theory, technology, and practice. New York, NY: Wiley VCH. ISBN 978-0-471-19037-0. McMaster, Marvin C. (2007). HPLC. doi:10.1002/0470079096. ISBN 978-0-471-75401-5.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.